Ansgar Hebborn

Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European Access Academy

Elaine Julian, Mira Pavlovic, Oriol Solà-Morales, Fabrizio Gianfrate et autres

OBJECTIVES: Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealing with remaining uncertainties as well as transparent and consistent …

ch, it, fr, de, nl, be (code pays fourni par la source)

How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments?

Elaine Julian, Fabrizio Gianfrate, Oriol Solà-Morales, Peter G. M. Mol et autres

OBJECTIVES: We conducted a multi-stakeholder survey to determine key areas where a joint European health technology assessment (HTA) could provide 'additional benefit' compared to the status quo of many parallel independent national and subnational assessments. METHODS: Leveraging three iterative Delphi cycles, a …

ch, it, nl, fr, be, de (code pays fourni par la source)

The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes

Giovanni Tafuri, Chantal Bélorgey, Carlo Favaretti, Edith Frénoy et autres

The European Network for Health Technology Assessment (EUnetHTA) organizes an annual Forum with stakeholders to receive feedback on its activities, processes, and outputs produced. The fourth edition of the EUnetHTA Forum brought together representatives of HTA bodies, patient organizations, healthcare professionals (HCPs), …

nl, fr, it, be, ch, gb, gr, no, se (code pays fourni par la source)

Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view

Giovanni Giuliani, Frédéric Chassagnol, Marlene Gyldmark, Ansgar Hebborn et autres

BACKGROUND: Health Technology Assessments (HTA) procedures differ substantially across the various European countries. We reviewed recent appraisals of a pharmaceutical manufacturer in three major European markets (France; Italy; Germany) and identified and categorized related decision drivers. METHODS: New marketing authorisation between January …

it, fr, de, ch (code pays fourni par la source)

HTA und aktuelle Herausforderungen: Harmonisierung, Real World Data und Surrogatparameter

Alric Rüther, K Herrmann, Ansgar Hebborn, Matthias Perleth et autres

Health Technology Assessment is one of the standard instruments in support of the decision-making to define the public health services both internationally and in the German health care system. Besides systematic reviews, benefit-harm-analyses, health economic evaluations, and, decision-analytic modelling, especially epidemiological and …

de, ch (code pays fourni par la source)

IS THE EU NET HTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE

Marlene Gyldmark, Kristian Lampe, Jörg Ruof, Johannes Pöhlmann et autres

OBJECTIVES: The HTA Core Model® was developed to improve the transferability of health technology assessment (HTA) between settings. The model has been used by HTA agencies but is also of interest to manufacturers, for improving internal evidence generation and communicating with other …

ch, dk, ca (code pays fourni par la source)

OP163 European Network for Health Technology Assessment Joint Action 3 Relative Effectiveness Pilots: Pharma Company Experience

Ansgar Hebborn, André Oberdiek, Jennifer Cain Birkmose, Marlene Gyldmark et autres

Introduction: More than 50 HTA agencies evaluate the clinical value of medicines in Europe, resulting in duplication of work for HTA agencies and manufacturers, and lengthy and variable time to reimbursement for patients across Europe. A consistent, single European relative clinical scientific …

Systematic overview of cost–effectiveness thresholds in ten countries across four continents

Ruth Schwarzer, Ursula Rochau, Kim R. Saverno, Beate Jahn et autres

AIM: To provide an overview of thresholds for incremental cost-effectiveness ratios (ICERs) representing willingness-to-pay (WTP) across multiple countries and insights into exemptions pertaining to the ICER (e.g., cancer). To compare ICER thresholds to individual country's estimated ability-to-pay. MATERIALS & METHODS: We included …

at, us, ch (code pays fourni par la source)

Results of an International Expert Task Force on a Health Technology Assessment Framework for Personalized Medicine in Cancer

Petra Schnell‐Inderst, Theresa Hunger, Agnes Luzak, A. Mayer et autres

A Comparison of International Health Technology Assessment Systems – Does The Perfect System Exist?

Anthony K. Kerr, C Monson Todd, Ansgar Hebborn, K. Ulyate

ch (code pays fourni par la source)

Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

Lothar Bergmann, Harald G. Enzmann, Karl Broich, Ansgar Hebborn et autres

de, ch, us, gb, at (code pays fourni par la source)

PHP170 The Swiss Health Technology Assessment (HTA) Consensus: Guiding Principles

Michael Schlander, C. Affolter, H. Sandmeier, Thomas B. Cueni et autres

ch (code pays fourni par la source)